In Latest US OTC Switch, Ivermectin 0.5% Lice Treatment Becomes Fully Nonprescription

 
• By Malcolm Spicer

FDA approved Arbor Pharmaceuticals' sNDA for an OTC switch of Sklice lice treatment. As it's been prescribed since its 2012 approval, Sklice will be available as a single-use lotion for topical treatment of head lice infestations in patients six months of age and older.

Arbor Pharmaceuticals’ Sklice was approved for OTC sales after being the only Rx ivermectin 0.5% approved for lice treatment available in the US.

More from Rx-to-OTC Switch

More from Health